Clinical Trial Info

Safety and Immunogenicity Study of 20vPnC in Healthy Children 15 Months Through 17 Years of Age

Authored by
Staff

This Phase 3 study is designed to evaluate the safety and immunogenicity of 20vPnC in 800 healthy children 15 months through 17 years of age.